Onxeo Logo

Onxeo

ISIN: FR0010095596 | Ticker: ALONX | LEI: 96950018AS30IUG0V528
Sector: Health CareSub-Industry: Biotechnology
Country: France

About Onxeo

Company Description

Onxeo is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions.

Our therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. Our approach is based upon unique mechanisms of action on DNA Damage Response. We focus on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.

We seek to transform breakthrough scientific opportunities into treatments through translational and clinical expertise, developing products to the stage where they are compelling opportunities for partners. Therefore, we are focused on advancing products from preclinical stage to optimal inflection points (usually phase 2 clinical proof-of-concept studies). Once proof of concept is established, we seek to monetize the assets.

Year founded

1997

Served area

Worldwide

Headcount

30

Headquarters

49 Avenue du Général Martial Valin, 75015 Paris – France

Filings & Publications

Sign up and we will give you access!

Insider Trades

Date Trading entity / Person Association Trade type Volume
09.06.23 None Other Other EUR 5,000,000.04
09.06.23 None Other Other EUR 1,999,999.96

Capital markets information

ISIN

FR0010095596

LEI

96950018AS30IUG0V528

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Euronext Paris

Main Stock Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.